NEW YORK (GenomeWeb) – US provider Intermountain Healthcare has signed a distribution deal allowing Taiwan's Prisma Biotech to sell the ICG100 tumor sequencing test in that country.
The next-generation sequencing-based ICG100 test provides analyzes 100 genes for patient-specific mutations that could suggest personalized drug treatments. Intermountain controls the rights to the next-generation sequencing-based test through a contract with Prisma's fully-owned subsidiary, ReadGene.
Financial and other details of the agreement were not disclosed.
"We are very excited to be a partner of Intermountain Precision Genomics to introduce the comprehensive, end-to-end service to Taiwan, including testing, the molecular tumor board, matching drugs, and monitoring the outcome," Prisma CEO Kevin Hung-Pin Tseng said in a statement.
Last month, Intermountain signed a similar deal with Singapore-based Asia Genomics, covering distribution of ICG100 in Southeast Asia.